What's in Hua Medicine Limited's pipeline?

Hua Medicine Limited has 3 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Hua Medicine Limited's portfolio?

Top competitors by shared drug class: Array BioPharma, AstraZeneca, Galderma R&D, Merck Sharp & Dohme LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hua-medicine-limited.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Hua Medicine Limited — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hua Medicine Limited pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Dorzagliatin tablets	Dorzagliatin tablets	marketed
HMS5552	HMS5552	phase 3	Glucokinase activator	Glucokinase (GCK)	Diabetes

Therapeutic area mix

Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Array BioPharma · 1 shared drug class
AstraZeneca · 1 shared drug class
Galderma R&D · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hua Medicine Limited:

Cite this brief

Drug Landscape (2026). Hua Medicine Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hua-medicine-limited. Accessed 2026-05-17.